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Abstract The Italian society of colo-rectal surgery
(SICCR) is dedicated to improving the study, prevention
and management of the diseases of the colon, rectum and
anus. One of the aims of the society is to establish guide-
lines to the treatment of these diseases. These guidelines
are based on the international literature and on the best
available evidence. Clinical practice guidelines are one of
the most important instruments to provide therapeutic
decision-making support, based on the best scientific evi-
dence available at the time. Guidelines are advisory and not
prescriptive, susceptible to continual variations secondary
to innovations and new scientific evidence. These guide-
lines are a guide for all colo-rectal surgeons and physicians
who approach anal cancer.
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Introduction
Clinical practice guidelines are one of the most important
instruments for any scientific society to provide some
therapeutic decision-making support, based on the best
scientific evidence available at the time.
Guidelines are advisory and not prescriptive, susceptible
to continual variations secondary to innovations and new
scientific evidence.
Italian society of colo-rectal surgery (Societa` Italiana di
Chirurgia Colorettale; SICCR) guidelines are intended for
the use of all colo-rectal surgeons, health care professionals
and patients who desire information.
Methodology
A MedLine search of English language references was
performed by using the following keywords: anal cancer,
anal squamous cell carcinoma, anal carcinoma, anal
intraepithelial neoplasia, anal tumors, anal canal carcinoma
and anal margin carcinoma.
The Cochrane library was also reviewed.
The levels of scientific evidence were adapted from
Cook et al. [1].
Epidemiology
Carcinoma of the anus is a rare entity that the incidence of
which has been rising over the last two decades, and which
constitutes 3 % of all gastrointestinal tract tumors.
In Western Europe, the average annual incidence of anal
carcinoma is 1–3 cases per 100,000 with a female preva-
lence (two to four times that of men [2]) and a highest
incidence during the sixth and seventh decades of life [3].
The annual incidence can be up to 35 per 100,000 in
men who practice anal-receptive sexual intercourse, and
those who are human immunodeficiency virus (HIV)
positive have twice the risk of those who are not [2].
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In particular, squamous cell carcinoma (the other names,
epidermoid or spinocellular, are no longer used) is the most
common histological type of anal carcinoma and consti-
tutes up to 80 % of all malignant anal tumors [4].
The clinical presentation is non-specific and may
include anorectal bleeding, soiling and pruritus. Pain and
the progressive growth of an anal mass are among the
presenting symptoms in only 1 of 3 cases [5].
The mass size at diagnosis is about 3–4 cm [6].
Etiology
Chromosome 11 deletions (11q22) or the short arm of
chromosome 3 (3p22), environmental factors such as cig-
arette smoking, sexual orientation and a high number of
sexual partners, anoreceptive intercourse, male homosex-
uality, viral infections of the anogenital area (human
papillomavirus (HPV) virus type 16 and 18) and immu-
nodeficiency are all considered as causative factors of anal
cancer [3, 6, 7].
The introduction of antiretroviral drugs has improved
the life expectancy of HIV-positive patients. This has
contributed to increasing the incidence of anal cancer in
this population.
HPV infection (type 16 in about 87 % of cases [8]) and
anogenital warts are closely associated with anal cancer.
Anal canal lesions are more often HPV positive than per-
ianal lesions. Ninety-five percent of anal canal cancer in
women and 83 % in men is HPV positive while cancer
located at the anal margin are HPV positive in only 80 %
of women and 28 % of men [8]. Because of this high
association with anal cancer, HPV is considered to be the
most important causative factor much like in cases of
cervical cancer [9–12].
In particular, HPV is involved in the pathogenesis of
anal intraepithelial neoplasia (AIN) which progresses from
dysplasia to invasive cancer. HPV type 16 seems to be
associated with a higher risk of malignant transformation
[13].
Other viral infections such as herpes simplex virus
(HSV) have been studied but are considered to play only a
marginal role in disease progression.
Anatomy and histological variants of malignant tumors
In the IUCC, American Joint Committee on Cancer
(AJCC) and World Health Organization (WHO) staging
systems, the anal canal is described as the last part of the
gastrointestinal tract extending from the anal ring at the
level of the puborectalis muscle (where the rectum enters
the pelvic floor) to the anal margin that is the junction of
the hair-bearing skin and the non-keratinizing squamous
epithelium of the distal anal canal.
Tumors of the anal canal can present different histo-
logical features. These guidelines refer to squamous cell
carcinoma (including the so-called cloacogenic variant)
which constitutes 80 % of all lesions of this area and
derives from transitional and squamous cell epithelium. In
some pathology literature, squamous cell carcinoma of
the anal canal is also described according to additional
histopathologic feature such as keratinization, presence of
mucin and abundance of basement membrane-like
material.
Less common is adenocarcinoma and mucinous adeno-
carcinoma of the anal glands or of fistula tracts that must be
distinguished from very low rectal cancers. Other uncom-
mon neoplasms of the anal canal include small cell carci-
noma, carcinoid and other neuroendocrine tumors,
malignant melanoma, squamous cell papilloma, papillary
hidradenoma, keratoacanthoma, mesenchymal and neuro-
genic tumors, lymphoma, leiomyosarcoma and secondary
tumors.
Tumors originating from the anal margin should be
staged as skin cancer: they can be squamous cell cancer,
basal cell cancer, Bowen’s or Paget’s disease.
This is an important distinction as skin cancers rarely
involve lymph nodes or lead to distant metastases [14–16].
Cancer of the anal canal
Diagnosis
Patients complain of anal bleeding, pain and sensation of a
mass in about 80 % of cases.
A disease-specific history and physical examination are
mandatory to evaluate predisposing factors, tumor exten-
sion and lymph node involvement.
Tissue biopsy is needed to establish the diagnosis. Ano-
rectal cytology may only be used as a screening tool [17].
About 20 % of patients present with synchronous nodal
disease while distant metastases develop in 10–17 % [18–
21]. Lesions growing above the dentate line usually
metastasize to mesorectal, pararectal and retroperitoneal
(paravertebral) nodes while those originating below the
dentate line metastasize to inguinal and femoral lymph
nodes. HIV-positive patients commonly present with pal-
pable enlarged nodes that are found to be histologically
positive only in 50 % of cases.
Sentinel lymph node (SLN) biopsy of inguinal nodes has
been proven to be a simple, safe and effective method for
staging patients with anal cancer. Accurate detection of
inguinal node metastases with this technique could obvi-
ate the need for prophylactic inguinal radiotherapy and
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eliminate related morbidity (e.g., inguinal fibrosis, external
genitalia edema, lower limb lymphedema, osteonecrosis of
femoral head, small bowel injury) which subsequently
develops in 33 % of irradiated patients [22].
(Level of Evidence: III; Grade of Recommendation: B).
During the diagnostic work up, endoscopic and radio-
logic evaluation should be performed. Colonoscopy is
indicated in patients at risk for large bowel cancer and in
Paget’s perianal disease.
Endoanal ultrasound is useful in assessing sphincter
involvement, tumor extension and local lymph node
metastases. Endoanal ultrasound tumor-node-metastasis
(uTNM) staging system was introduced in 2002 [23].
Nowadays, only a few studies with small numbers have
evaluated the role of endoanal ultrasound in anal cancer
staging. To date its main role is follow-up evaluation of
patients treated with chemoradiotherapy (CRT) for squa-
mous cell tumor of the anal canal [24]. EUS staging of anal
canal cancer is reported in Table 1.
Computed tomography (CT) scanning should be per-
formed in the pretreatment evaluation of anal cancer to
exclude metastatic disease. Positron emission tomography
(PET) scanning as an adjunct to CT identifies sites of
metastasis not observed on CT in 25 % of cases [25]. Almost
20 % of patients with inguinal nodes that are negative on both
physical examination and CT scan are positive on PET [26].
PET/CT proved useful in initial staging perirectal/pelvic
or inguinal lymph nodes, causing a change in radiation
fields in 16–35 % of patients [25–29]. However, upstaging
related to lymph node metastases might have been over-
estimated, as up to 31 % of inguinal metastases identified
by PET/CT are reportedly false positives [30].
(Level of Evidence: IV; Grade of Recommendation: C).
Currently, inguinal lymph nodes are better staged by
sentinel node biopsy [30].
As far as the role of virology in the diagnostic process is
concerned, diagnosis of HIV and/or HPV infection do not
imply a worse prognosis and therefore do not influence the
treatment plan, at least for patients with a CD4 count[200.
However, in HIV-positive patients anal cancer may be
multifocal.
(Level of Evidence: IV; Grade of Recommendation: B).
Role of screening
High-risk groups such as homosexual men, individuals who
practice anal intercourse, immunodepressed individuals
and women affected by cervical intraepithelial neoplasia
(CIN) III should be screened for anal cancer and AIN.
Screening should be performed with anal cytology and
high-resolution anoscopy.
HPV infection should be considered in the evaluation of
the progression of precancerous lesions such as AIN to anal
cancer [13]. Due to the close relationship of cervical cancer
with HPV infection, a gynecological exam should be per-
formed with the aim of screening for synchronous cervical
cancer.
Role of vaccines
Prophylactic vaccines against human papillomavirus have
shown nearly 100 % efficacy against high-grade lesions
of the cervix, vulva and vagina in uninfected women
under 26 years of age. These results suggest vaccines will
have a role in the prevention of anal intraepithelial neo-
plasia and squamous cell carcinoma of the anus in both
sexes [31, 32].
Staging
The most recent TNM staging version, published by the
AJCC [33] is based on clinical and surgical–pathological
assessment and more precisely reflects prognostic factors,
specifically the size of the tumor and the regional lym-
phatic spread (Table 2).
Treatment
Management of anal cancer has changed during the last
decades from a purely surgical approach, with a 5-year
survival rate ranging from 30 to 80 %, to combined CRT
with surgery indicated in case of residual or recurrent
tumor [34]. However, no significant change in overall
survival has been reported so far [17, 19, 20, 22] when this
approach is compared with traditional surgery.
A local surgical approach may be appropriate only for
selected small lesions and for carcinoma in situ [35].
Tumor radiation alone is at times adopted for small lesions
up to T2 with the radiation dose of 40–50 Gy and can be
curative in 70–80 % of cases [6, 36].
With a radiation field extended not only to the tumor site
but also to the pelvis and inguinal lymph nodes, a success
rate of 60–80 % can be achieved [37, 38]. To follow are the
recommendations for the treatment of the most common
presentations of the disease.
Table 1 Cancer of the anal canal—endoanal ultrasound staging
uT1 (tumor confined to the submucosa)
uT2 (lesion invading the sphincter complex)
The uT2 lesions were divided into uT2a lesions (tumor invading
only the internal sphincter) and uT2b lesions (tumor invading
also the external sphincter)
uT3 (lesion invading through the sphincter complex into the
perianal tissue) and
uT4 (tumor invading adjacent structures)
Tech Coloproctol
123
Any T any N: polychemotherapy ? radiotherapy
Radiotherapy (RT) with concurrent chemotherapy is the
current standard of care for patients with localized squa-
mous cell cancer of the anal canal.
The majority of patients treated with CRT have excel-
lent outcomes, with 5-year overall survival rates of
approximately 75 % [15, 19].
(Level of Evidence: I; Grade of Recommendation: A)
Since its introduction by Nigro in 1979 [39, 40] (5-Fu,
mitomycin and radiation), several studies have demon-
strated the greater efficacy of the association of RT with
chemotherapy with lower rates of local failure and recur-
rence and a smaller number of patients requiring a colos-
tomy when compared with RT alone [35].
(Level of Evidence: I; Grade of Recommendation: A).
Pelvic RT can cause late toxicity, adversely impact
bowel and sexual function and adversely affect quality of
life (QoL). Younger patients reported worse QoL scores.
Modern techniques of RT, such as intensity-modulated
radiation therapy (IMRT), could potentially reduce toxicity
by reducing the radiation dose to the anorectal region and
genitalia.
The association of multiple chemotherapeutic agents
with RT results in a better synergistic effect [16, 22, 41] is
currently recommended.
(Level of Evidence: I; Grade of Recommendation: A).
RT is usually delivered at a total dose varying between
45 and 59 Gy. Higher doses without prolonged breaks in
treatment have been shown to be more effective. The need
for a diverting colostomy increases with the increase in the
RT dose. The above RT dose should ideally be delivered
during a period of 6 weeks [16, 42–45].
(Level of Evidence: III; Grade of Recommendation: B).
In HIV-positive patients, a good tolerance of CRT can
be predicted if the CD4 count is above 200 [46].
Table 2 Cancer of the anal canal
The TNM system
The TNM system for staging contains 3 key pieces of information
T describes the size of the primary tumor, measured in
centimeters (cm) and whether the cancer has spread to organs
next to the tumor
N describes the extent of spread to nearby (regional) lymph
nodes
M indicates whether the cancer has metastasized (spread) to
other organs of the body
Numbers or letters appear after T, N and M to provide more details
about each of these factors
The numbers 0 through 4 indicate increasing severity
The letter X means ‘‘cannot be assessed’’ because the
information is not available
The letters ‘‘is’’ mean ‘‘carcinoma in situ,’’ which means the
tumor is contained within the top layer of anal tissue and has not
yet reached deeper layers of tissue
The possible values for T are
TX: Primary tumor cannot be assessed
T0: No evidence of primary tumor
Tis: Carcinoma in situ
T1: The tumor is 2 cm (about 4/5 inch) across or smaller
T2: Tumor is between 2 and 5 cm in size (about 1–2 inches)
T3: Tumor is larger than 5 cm
T4: Tumor of any size that is growing into nearby organ(s), such
as the vagina, urethra (the tube that carries urine out of the
bladder), prostate gland or bladder
The possible values for N are
NX: Regional lymph nodes cannot be assessed
N0: No regional lymph node spread
N1: Spread to lymph nodes near the rectum
N2: Spread to lymph nodes on one side of the groin and/or pelvis
N3: Spread to lymph nodes near the rectum and in the pelvis or
groin or to both sides of the groin or pelvis
The M values are
MX: Presence of distant metastasis cannot be assessed
M0: No distant spread
M1: Distant spread to internal organs or lymph nodes of the
abdomen
Stage grouping
To make this information more helpful, these TNM descriptions
can be grouped together into a simpler set of stages, labeled
stage 0 through stage IV
Stage 0: Tis, N0, M0: Stage 0 is very early cancer (or precancer)
that exists only in the top layer of anal tissue. This stage is also
known as carcinoma in situ
Stage I: T1, N0, M0: The cancer cells have spread beyond the
top layer of anal tissue and the tumor is no longer carcinoma
in situ. The tumor is less than 2 cm (about 4/5 inch) in size. It
has not spread to lymph nodes or distant sites
Stage II: T2 or 3, N0, M0: The cancer is larger than 2 cm in size,
but it has not spread to nearby organs or lymph nodes. It has not
spread to distant sites
Table 2 continued
Stage IIIA: (T1–3, N1, M0) or (T4, N0, M0): The cancer can be
any size and either has spread to the lymph nodes around the
rectum (N1) or it has grown into nearby organs (T4), such as the
vagina or the bladder without spreading to nearby lymph nodes.
It has not spread to distant sites
Stage IIIB: (T4, N1, M0), or (Any T, N2–3, M0): Either the
cancer has grown into nearby organs, such as the vagina or the
bladder, and has also spread to lymph nodes around the rectum,
or it can be of any size but has spread to lymph nodes in the
groin, with or without spread to lymph nodes around the rectum.
It has not spread to distant sites
Stage IV: Any T, Any N, M1: The cancer has spread to distant
organs or tissues. It can be any size and may or may not have
spread to lymph nodes
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Persistent progressive or recurrent disease
Local failure occurs in up to 30 % of patients and is equally
divided between persistent (if the neoplasms is found up to
3 months after the end of CRT), progressive (if the neoplasm
grows in size during the CRT) and recurrent (if the neo-
plasms reappears 3 or more months after the end of CRT).
The waiting time from the end of CRT to the final
evaluation of the treatment is considered to be 8–10 weeks.
The duration of the interval between CRT and final eval-
uation is still under debate with some authors suggesting a
longer period of observation.
Persistent disease is re-evaluated at 4 weeks, then, the
cases where a regression is noted are followed. Those
without regression as those clearly progressing are best
treated with an abdominoperineal resection (APR) which is
an effective option for this indication with a 5-year survival
rate of 24–58 % [47].
(Level of Evidence III; Grade of Recommendation: B).
Survival after APR resection is longer for patients with
persistent disease compared with patients with recurrent
disease [7, 22, 47–51]. APR may also be beneficial in the
treatment of local RT-induced complications such as
stenosis, ulceration or incontinence. An additional boost of
CRT has been suggested in a small number of reports but
its efficacy is debated [17].
In case of progressive disease, no response to CRT,
extrapelvic recurrence or local recurrence after APR,
treatment with multiple chemotherapeutic agents is indi-
cated [52, 53].
(Level of Evidence III; Grade of Recommendation: B).
Synchronous inguinal lymph node involvement com-
pletely regresses after CRT in 90 % of cases [15].
Metachronous lymph node involvement, seen in
10–20 % of patients, usually within 6 months from the end
of treatment, may also respond to CRT [41].
In case of persistent lymph node disease, surgical
removal is indicated.
Follow-up
A clinical evaluation with digital rectal examination, proc-
toscopy and abdominal-inguinal palpation is recommended.
Follow-up with serial endoanal ultrasound has recently
gained popularity but the results are still preliminary [23, 24].
(Level of Evidence: IV; Grade of Recommendation: B).
Follow-up begins at 6–12 weeks after the end of CRT
and needs to be repeated every 3–6 months. Endorectal
ultrasound (ERUS) and CT scan indicated in case recur-
rence are suspected [7, 54–56].
The proposed flow chart showing the diagnostic and
therapeutic algorithm for anal canal cancer is reported in
Table 3.
Anal margin
Diagnosis
It may be difficult to differentiate between anal margin and
anal canal in the case of large tumors.
The differential diagnosis between anal canal and anal
margin tumors is useful because of the difference in
treatment and prognosis (generally better for anal margin
lesions) between the two [6].
Bowen’s and Paget’s diseases of the anal margin can be
associated with other malignancies (5 % for Bowen up to
50 % for Paget) [6].
This extramammary form of Paget’s represents less than
1 % of anal disease and 6.5 % of all cases of Paget’s dis-
ease [6].
This tumor can recur after radical surgery and has a
capacity of metastatic spread: its aggressive behavior
imposes a long-term follow-up with frequent clinical,
radiological and endoscopic controls.
The diagnostic work up for anal margin tumors is that
the same as the one highlighted for anal canal tumors.
Clinical staging
Anal margin squamous cell carcinomas are staged like skin
cancer, according to the AJCC [33].
Treatment
A local excision (1 cm margin) is indicated in early
squamous lesions such as T1, N0,\2 cm, microinvasive or
carcinoma in situ, and well-differentiated tumors, similarly
to skin lesions, with a 80 % 5-year survival rate [57].
In case of more extended lesions or doubtful inguinal or
regional lymph nodes, adjuvant radiation therapy is
suggested.
More locally advanced lesions such as T3 or T4 need to
be treated with radiation of either inguinal regions or pelvis
associated with chemotherapy as previously described for
anal canal lesions.
A more extended surgical approach such as APR is
indicated in case of CRT failure and in case of incontinent
patients with large, bulky cancers infiltrating the sphincter
and pelvic muscles.
The proposed flow chart showing the diagnostic and
therapeutic algorithm for cancer of anal margin is reported
in Table 4.
Anal intraepithelial neoplasia
AIN has been called, among other things, dysplasia, carci-
noma in situ, anal squamous intraepithelial lesion, Bowen’s
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disease. It has some characteristics in common with CIN and
in fact is classified according to cervical cytology.
High-grade anal intraepithelial neoplasia, also referred
to as anal squamous carcinoma in situ, or Bowen’s disease
of the anus, make up less than 1 % of all digestive system
cancers.
They can be accidentally found in the anal transitional
area as in the anal margin area.
AIN is considered as a precursor to anal squamous cell
carcinoma: AIN Grade 1 correspond to low-grade squa-
mous intraepithelial lesion (LSIL), AIN II–III stands for
high-grade squamous intraepithelial lesion (HSIL) that
is sometimes referred to as anal carcinoma in situ and
Bowen’s disease.
Up to 80 % of AIN are believed to develop from HPV
16 and 18 infections.
Diagnosis
Incidentally diagnosed, they can present as an eczematoid
area with papules, often white, irregular and fissured.
A high-level suspicious history should be taken, with
particular attention to signs, symptoms and predisposing
factors.
Basic diagnostic work up includes clinical inspection of
the perianal area, digital rectal examination, and anal
cytology.
These lesions are more common in HIV patients, espe-
cially in HIV-positive men having sex with men (MSM).
A compromised immune system, both in male and in
female is an important risk factor.
HIV seropositivity, like immunosuppression for organ
transplantation or for specific diseases, is associated with AIN
and its progression to high-grade squamous intraepithelial
lesions. This progression has been observed to occur in about
10–50 % of HIV-positive patients within 2 years [58, 59].
HPV infection associated with AIN is well demon-
strated. Despite the limited data available about the path-
ophysiologic effects of HPV (subtypes 16 and 18), a loss of
tumor suppressor protein p53 has been described as well as
some gene aberrations and alterations [58].
These associations can be simply superimposed with
cervical cancer natural history [60–62].
As reported for CIN, Papanicolaou smear cytological
examination can be used for screening and follow-up of AIN.
(Level of Evidence III; Grade of Recommendation: C).
Nevertheless, high-resolution anoscopy-directed biopsy
is still considered as the gold standard for AIN diagnosis.
Treatment
The treatment of choice is surgical resection with anal
mapping.
Although the main treatment modality for treating per-
sistent/recurrent AIN is surgery, an alternative approach
using external beam radiation has been proposed.
As a well-established precursor of squamous cell car-
cinoma, AIN observation is not considered an appropriate
strategy [63].
(Level of Evidence: IV; Grade of Recommendation: C).
New drugs with an immunomodulatory effect, such as
5 % imiquimod cream (response rate more than 50 %) [64]
or chemotherapeutics such as 5 % 5-fluorouracil cream
(initial response rate of 90 %) are indicated for AIN [65].
(Level of Evidence: IV; Grade of Recommendation: C).
Photodynamic therapy has been suggested in some
cases, but its effectiveness has been shown only in case
reports [66].
(Level of Evidence: V; Grade of Recommendation: D).
Surgical excision (wide local excision, targeted destruc-
tion, infrared coagulation) and careful clinical follow-up
similar to what is indicated for CIN have been adopted to
treat AIN and to prevent its progression [67–70].
(Level of Evidence: III; Grade of Recommendation: C).
Follow-up
Considering the risk of progression to squamous cell car-
cinoma, surveillance is mandatory.
This can be performed at 6-month follow-up unless
dysplasia is still present. High-resolution anoscopy with
magnification and/or the application of Lugol’s solution
can be performed especially in those patients with risk
factors [70].
Table 3 Diagnostic and therapeutic algorithm for anal canal cancer
Biopsy Histopathological diagnosis of squamous cell carcinoma
Staging Clinical evaluation: digital anorectal
evaluation ? inguinal evaluation
Instrumental evaluation: chest X-ray or CT
scan ? anoscopy ? pelvic MRI or CT scan or
PET-CT; eventual sentinel lymph node biopsy
HIV test and CD4 count ? gynecological exam
(screening for cervical cancer)
Treatment Any T any N: polychemotherapy ? radiotherapy
Evaluate in 8–12 weeks
Complete remission: evaluation every 3–6 months for 5 years
(clinical ? radiological evaluation)
Local recurrence: abdominoperineal resection
Distant metastasis: polychemotherapy or clinical trial
Persistent disease—histopathological confirmation: re-evaluation at
4 weeks
No regression or progression: treatment as a progressive disease
Regression: evaluate in 2 months
Progressive disease—histopathological confirmation:
abdominoperineal resection ± then follow-up
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(Level of Evidence: III; Grade of Recommendation: B).
The proposed flow chart showing the diagnostic and
therapeutic algorithm for AIN is reported in Table 5.
Verrucous carcinoma
This tumor, also called giant condyloma (Buschke–
Lowenstein tumor), appears as a cauliflower-like lesion
that can involve the anogenital area.
Some of these lesions are HPV positive (subtypes 6 and
11).
Intermediate between classical condyloma and squa-
mous cell cancer, it is characterized by a local invasive
behavior with a combination of exophytic and endo-
phytic growth with very rare metastasis and a variable
risk of showing malignant transformation (around 42 %)
[71].
Diagnosis
It presents like an exophytic tumor of the genital or peri-
anal area, with ulceration and sometimes fistulae and
sinuses. It is more commonly seen in men than in women
(2–3 vs. 1) and immunocompromised patients.
The histological appearance of this cancer is similar to
that of condyloma acuminata, but with a tendency to
compress and displace deeper tissues, without basement
membrane disruption.
Physical examination and a dedicated diagnostic work
up (the same as the one highlighted for anal canal and
margin tumors) are useful to choose the right treatment
regimen.
Treatment
A wide local excision is indicated to avoid malignant
transformation, and because of the high number of
recurrences.
Other treatment modalities such as chemotherapy or
imiquimod may be attempted to avoid mutilating surgical
interventions [72].
Follow-up
An established and rigorous follow-up is necessary
because of frequent recurrences and possible malignant
transformation.
Conclusions
Cancer of the anal canal is still a challenge. Despite the
efficacy showed by the introduction of RT into the treat-
ment plan, a lot of work needs to be done to better define
this disease.
Conflict of interest None.
Table 4 Diagnostic and therapeutic algorithm for anal margin cancer
Biopsy Histopathological diagnosis of squamous cell carcinoma
Staging Clinical evaluation: digital anorectal
evaluation ? inguinal evaluation
Instrumental evaluation: chest X-ray or CT
scan ? anoscopy ? pelvic MRI or CT scan or PET-
CT; eventual sentinel node biopsy
HIV test and CD4 count ? gynecological exam
(screening for cervical cancer)
Treatment T1, N0 \ 2 cm, microinvasive or carcinoma in situ, well
differentiated: local excision with 1 cm margin
T2–4, any N: polychemotherapy ? radiotherapy ?
evaluate in 8–12 weeks
Complete remission: evaluation of every 3–6 months for 5 years
(clinical ? radiological evaluation)
Local recurrence: abdominoperineal resection
Distant metastasis: polychemotherapy or clinical trial
Progressive disease—histopathological confirmation:
abdominoperineal resection ± polychemotherapy ? RT—then
follow-up
Persistent disease—histopathological confirmation: re-evaluation at
4 weeks
No regression–progression: treatment as a progressive disease
Regression: evaluate in 2 months
Table 5 Diagnostic and therapeutic algorithm for anal intraepithelial
neoplasia—(AIN)
Biopsy Histopathological diagnosis of
AIN GRADE 1—low-grade squamous intraepithelial
lesion (LSIL)
AIN GRADE 2—high-grade squamous intraepithelial
lesion (HSIL)
Dysplasia, carcinoma in situ, anal squamous
intraepithelial lesion, Bowen disease, etc.
Anal cytology: Papanicolaou smear cytological
examination
Staging Clinical evaluation: digital anorectal evaluation ?
inguinal evaluation
Instrumental evaluation: high-resolution anoscopy
HIV test and CD4 count ? gynecological exam
(screening for cervical cancer)
Treatment Surgical resection with anal mapping (wide local
excision, targeted destruction, infrared coagulation)
Complete remission: evaluation every 6 months for 5 years
(clinical ? anoscopy evaluation)
Recurrent
disease
Histopathological confirmation
AIN: local excision and follow-up
Anal margin cancer: see dedicated chapter
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